Mistletoe treatment induces GM-CSF- and IL-5 production by PBMC and increases blood granulocyte- and eosinophil counts: A placebo controlled randomized study in healthy subjects

European Journal of Medical Research

Volumn 10, Issue 10, 2005, Pages 411-418

  Huber, Roman ^a   Rostock, M ^a   Goedl, R ^a   Ludtke R ^b   Urech, K ^c   Buck, S ^d   Klein, R ^d  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Karl und Veronica Carstens Stiftung   (Germany)

^c Institute Hiscia   (Switzerland)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Eosinophils; Granulocyte macrophage colony stimulating factor; Mistletoe lectin; T helper 2 response

Indexed keywords

ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 5; ISCADOR QUERCUS SPEZIAL; PLACEBO; PLANT EXTRACT; UNCLASSIFIED DRUG; VISCOTOXIN; VISCUM ALBUM EXTRACT; VISCUM ALBUM LECTIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEPLETION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG FORMULATION; DRUG INDICATION; DRUG PURIFICATION; EOSINOPHIL; GRANULOCYTE; HUMAN; HUMAN EXPERIMENT; LEUKOCYTE DIFFERENTIAL COUNT; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN INDUCTION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VOLUNTEER;

ADULT; DOUBLE-BLIND METHOD; EOSINOPHILS; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; GRANULOCYTES; HUMANS; INTERLEUKIN-5; LEUKOCYTE COUNT; LEUKOCYTES, MONONUCLEAR; MALE; PHYTOTHERAPY; PLANT EXTRACTS; PLANT PROTEINS; PROSPECTIVE STUDIES; VISCUM ALBUM;

EID: 27744562512     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Weis J, Bartsch HH, Hennies F, Rietschel M, Heim M, Adam G, Gärtner U, Ammon A (1998) Complementary Medicine in cancer patients: demands, patients attitudes and psychological believes. Oncology 21:144-149
2. Steiner R (1920) Geisteswissenschaft und Medizin. Rudolf Steiner Edition, Dornach 1976
3. Kienle GS, Berrino F, Büssing A, Portalupi E, Rosenzweig S, Kiene H (2003) Mistletoe in cancer - a systematic review on controlled clinical trials. Eur J Med Res 8: 109-119
4. Schumacher K, Schneider B, Reich G, Stiefel T, Stoll G, Bock PP, Hanisch J, Beuth J (2003) Influence of postoperative complementatry treatment with lectin-standardized mistletoe extract on breast cancer patients. A controlled epidemiological multicentric retrolective cohort study. Anticancer Res 23: 5081-5087
5. Schultze JL, Stettin A, Berg PA (1991) Demonstration of specifically sensitized lymphocytes in patients treated with an aqueous mistletoe extract. Klin Wochenschr 69: 397-403
6. Hajto T, Hostanka K, Frei K, Rordorf C, Gabius HJ (1990) Increased secretion of TNFa, IL-1 and IL-6 by human mononuclear cells exposed to b-galactoside-specific lectin from clinically applied mistletoe extract. Cancer Res 50: 3322-3326
7. Hajto T, Hostanska K, Gabius HJ (1989) Modulatory potencies of the beta-galactoside-specific lectin from mistletoe extracts (Iscador) on the host defense system in vivo in rabbits and patients. Cancer Res 49: 4803-4808
8. Klein R, Classen K, Berg PA, Lüdtke R, Werner M, Huber R (2002) In vivo-induction of antibodies to mistletoe lectin-1 and viscotoxin by exposure to aqueous mistletoe extracts: a randomised double-blinded placebo controlled phase I study in healthy individuals. Eur J Med Res 7: 155-163
9. Stein GM, Henn W, V.Laue HB, Berg PA (1998) Modulation of the cellular and humoral immune responses of tumor patients by mistletoe therapy. Eur J Med Res 3:194-202
10. Stein GM, Schaller G, Pfüller U, Schietzel M, Büssing A (1999) Thionins from Viscum album L: Influence of the viscotoxins on the activation of granulocytes. Anticancer Res 19: 1037-1042
11. Van Wely M, Stoss M, Gorter RW (1999) Toxicity of a standardized mistletoe extract in immunocompromised and healthy individuals. Am J Ther 6/1: 37-43
12. Huber R, Klein R, Berg PA, Lüdtke R, Werner M (2002) Effects of a lectin- and a viscotoxin-rich mistletoe preparation on clinical and hematological parameters: a placebo controlled evaluation in healthy subjects. J. Alternative Compl Med 8: 857-866
13. Huber R, Lüdtke R, Klassen M, Müller-Buscher G, Wolff-Vorbeck G, Scheer R (2001) Effects of a mistletoe preparation with defined lectin content on chronic hepatitis C: an individually controlled cohort study. Eur J Med Res 6: 399-405
14. Stein GM, Berg PA (1999) Characterisation of immunological reactivity of patients with adverse effects during therapy with an aqueous mistletoe extract. Eur J Med Res 4: 169-177
15. Sanderson CJ (1992) Interleukin-5, eosinophils and disease. Blood 79: 3101
16. Wong CK, Zhang J, Ip WK, Lam CW (2002) Intracellular signal transduction in eosinophils and its clinical significance. Immunopharmacol Immunotoxicol 24: 165-186
17. Mosman TR, Sad S (1996) The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 17: 138-146
18. Romagnani S (1996) Th1 and Th2 in human disease. Clin Immunol Immunopathol 80: 225-235
19. Hajto T (1986) Immunomodulatory effects of iscador: a Viscum album preparation. Oncology 43 Suppl 1: 51-65
20. Buchsel PC, Forgey A, Grape FB, Hamann SS (2002) Granulocyte macrophage colony-stimulating factor: current practice and novel approaches. Clin J Oncol Nurs 6: 198-105
21. Belardelli F, Ferrantini M (2002) Cytokines as a link between innate and adaptive antitumor immunity. Trend Immunol 23: 201-208
22. Urech K, Schaller G, Ziska P, Giannattasio M (1995) Comparative study on the cytotoxic effect of viscotoxin and mistletoe lectin on tumor cells in culture. Phytotherapy Research 9(1): 49-55
23. Jäggy C, Musielski H, Urech K, Schaller G (1995) Quantitative determination of lectins in mistletoe preparations. Arzneim Forsch/Drug Res 45 (8): 905-909
24. Barth H, Berg PA, Klein R (2003) Methods for the in vitro determination of an individual disposition towards TH1- or TH2-reactivity by the application of appropriate stimulatory antigens. Clin Exp Immunol 134: 78-85
25. Heiny BM, Beuth J (1994) Mistletoe extract standardized for the galactoside-specific lectin (ML-1) induces beta-endorphin release and immunopotentiation in breast cancer patients. Anticancer Res 14: 1339-1342
26. Hostanska K, Hajto T, Spagnoli GC, Fischer J, Lentzen H, Herrmann R (1995) A plant lectin derived from Viscum album induces cytokine gene expression and protein production in cultures of human peripheral blood mononuclear cells. Nat Immun 14: 295-304
27. Cuschieri A, Talbot IC, Weeden S (2002) Influence of pathological tumour variables on long-term survival in resectable gastric cancer. Br J Cancer 86: 674-679
28. Fernandez-Acenero MJ, Galindo-Gallego M, Sanz J, Aljama A (2000) Prognostic influence of tumor-associated eosinophilic infiltrate in colorectal carcinoma. Cancer 88: 1544-1548
29. Clark SC, Kamen R (1987) The human hematopoietic colony-stimulating factors. Science 236: 1229
30. Hill HC, Conway TF, Sabel MS, Jong YS, Mathiowitz E, Bankert RB, Egilmez NK (2002) Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease. Cancer Res 62: 7254-7263
31. Dranoff G (2002) GM-CSF-based cancer vaccines. Immunol Rev 188: 147-154
32. Stein GM, Büssing A, Schietzel M (2002) Stimulation of the maturation of dendritic cells in vitro by a fermented mistletoe extract. Anticancer Res 22: 4215-4219
33. Burney IA, Salam A, Jat AA, Iqbal MP, Siddiqui T, Khan MA, Smego RA Jr. (2003) Comparison of low-dose versus standard colony stimulating factor in patients with chemotherapy-induced febrile neutropenia. Oncology 65: 283-284
34. Berghmans T, Paesmans M., Lafitte JJ, Mascaux C., Meert AP, Jacquy C., Burniat A., Steels E., Vallot F., Sculier JP (2002) Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis Support Care Cancer 10: 181-188